Stephen E. Spurgeon
A5003766253- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Immunodeficiency and Autoimmune Disorders
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Acute Lymphoblastic Leukemia research
- Advanced Breast Cancer Therapies
- CNS Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- PI3K/AKT/mTOR signaling in cancer
- Ubiquitin and proteasome pathways
- Prostate Cancer Diagnosis and Treatment
- Protein Degradation and Inhibitors
- HER2/EGFR in Cancer Research
- Prostate Cancer Treatment and Research
- Multiple Myeloma Research and Treatments
- Glycosylation and Glycoproteins Research
- Cancer Immunotherapy and Biomarkers
- Cutaneous lymphoproliferative disorders research
- Histone Deacetylase Inhibitors Research
- Computational Drug Discovery Methods
- Cancer-related Molecular Pathways
- T-cell and Retrovirus Studies
Oregon Health & Science University
2016-2025
The University of Texas MD Anderson Cancer Center
2022
Lund University
2022
Repatriation General Hospital
2022
Skåne University Hospital
2022
Royal Adelaide Hospital
2022
OHSU Knight Cancer Institute
2012-2021
City Clinical Hospital
2019
University of Pennsylvania
2017
University of Rochester
2016
Bruton's tyrosine kinase (BTK) is a mediator of the B-cell–receptor signaling pathway implicated in pathogenesis B-cell cancers. In phase 1 study, ibrutinib, BTK inhibitor, showed antitumor activity several types non-Hodgkin's lymphoma, including mantle-cell lymphoma.
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity genomic, transcriptomic, and clinical annotations for large cohort AML patients, which facilitated discovery functional genomic correlates. Here, we present dataset that has been harmonized our initial report to yield cumulative 805 patients (942 specimens). show strong cross-cohort concordance identify features response. Further, deconvoluting...
Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab followed by maintenance therapy older patients untreated mantle-cell lymphoma.
Kinases are dysregulated in most cancers, but the frequency of specific kinase mutations is low, indicating a complex etiology dysregulation. Here, we report strategy to rapidly identify functionally important targets, irrespective pathway dysregulation, ultimately enabling correlation patient genetic profiles clinically effective inhibitors. Our methodology assessed sensitivity primary leukemia samples panel 66 small-molecule inhibitors over 3 days. Screening 151 revealed wide diversity...
BACKGROUND Most patients with chronic lymphocytic leukemia (CLL) present multiple comorbidities. Although comorbidities negatively affect outcomes for treated chemoimmunotherapy, their impact on who receive targeted therapies is unknown. METHODS This multicenter, retrospective analysis evaluated the significance of comorbidities, as assessed by Cumulative Illness Rating Scale (CIRS), among CLL ibrutinib. RESULTS One hundred forty‐five received ibrutinib (80% in a relapsed/refractory...
The combination of venetoclax and dasatinib is synergistically effective in treating Philadelphia chromosome–positive ALL.
BACKGROUND: Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein present on many cancers. Zilovertamab vedotin (ZV) antibody–drug conjugate comprising a monoclonal antibody recognizing extracellular ROR1, cleavable linker, and the anti-microtubule cytotoxin monomethyl auristatin E. METHODS: In this phase 1, first-in-human, dose-escalation study, we accrued patients with previously treated lymphoid cancers to receive ZV every 3 weeks until occurrence of cancer...
There is a paucity of large-scale data delineating outcomes and prognostication older patients with primary central nervous system lymphoma (PCNSL). We retrospectively analyzed 539 newly-diagnosed PCNSL ages ≥60 years across 20 U.S. academic centers. The median age was 70 (range 60-88); at least one geriatric syndrome present in 46%; the Cumulative Index Ratings Scale-Geriatrics (CIRS-G) score 6 (range, 0-27); 36% had impairment activities daily living (ADL). most common induction regimens...
6631 Background: The class I phosphatidylinositol 3-kinases (PI3Ks) regulate cellular functions relevant to oncogenesis. Expression of the PI3K p110δ isoform (PI3Kδ) is restricted cells hematopoietic origin. CAL-101 an isoform-selective inhibitor PI3Kδ that induces apoptosis chronic lymphocytic leukemia (CLL) cells. Methods: This phase study evaluated in patients with previously treated hematologic cancers. was administered orally 1 or 2 times per day (QD BID) continuously 28-day cycles,...
// Russell T Burke 1 , Sarah Meadows 2 Marc M Loriaux 1,4 Kevin S. Currie 3 Scott A. Mitchell Patricia Maciejewski Astrid Clarke Julie Dipaolo Brian J. Druker 1,5 Lannutti ,and Stephen E. Spurgeon 1,6 Knight Cancer Institute, Oregon Health & Science University, Portland, OR. Gilead Sciences Inc, Seattle, WA Branford, CT 4 Division of Pathology, OR 5 Howard Hughes Medical Bethesda, MD 6 Hematology and Oncology, University Correspondence: Spurgeon, email: Keywords : Chronic Lymphocytic...
Abstract Pevonedistat (TAK924) is a Nedd8-activating enzyme inhibitor with preclinical activity in non-Hodgkin lymphoma (NHL). This open-label, Phase I, multicenter, investigator-sponsored study enrolled patients relapsed/refractory (R/R) NHL and chronic lymphocytic leukemia (CLL). The primary objective was safety. given intravenously on days 1, 3, 5 of 21-day cycle for 8 cycles at five dose levels (15 to 50 mg/m 2 ); ibrutinib administered 420 or 560 mg orally daily continuously. Eighteen...
Abstract Although Bruton tyrosine kinase inhibitors (BTKis) are generally well tolerated and less toxic than chemotherapy alternatives used to treat lymphoid malignancies, BTKis like ibrutinib have the potential cause new or worsening hypertension (HTN). Little is known about optimal treatment of BTKi-associated HTN. Randomly selected patients with malignancies on a BTKi antihypertensive drug(s) at least 3 months follow-up data were sorted into 2 groups: those diagnosed HTN before initiation...